Technological advances in the treatment of DM and the availability of affordable and high-quality insulin analogs have enabled proper metabolic control and increased the life expectancy of patients living with T1DM to be in line with those who do not have DM [10]. This evidence concerns the gene INS and diabetes mellitus.